JOP20210138A1 - طرق علاج السرطان في نماذج تأوي طفرات esr1 - Google Patents
طرق علاج السرطان في نماذج تأوي طفرات esr1Info
- Publication number
- JOP20210138A1 JOP20210138A1 JOP/2021/0138A JOP20210138A JOP20210138A1 JO P20210138 A1 JOP20210138 A1 JO P20210138A1 JO P20210138 A JOP20210138 A JO P20210138A JO P20210138 A1 JOP20210138 A1 JO P20210138A1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer
- methods
- estrogen receptor
- treating cancer
- receptor alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
تم الكشف هنا عن طرق معالجة سرطان إيجابي ألفا لمستقبلات هرمون الاستروجين المقاوم للعقاقير في مريض له مستقبل استروجين متحولة ألفا، وهي طريقة تشتمل على إعطاء المريض كمية فعالة علاجيًا من إيلاسيسترانت، أو ملح مقبول صيدلانيًا أو مذيب منه، حيث يشتمل مستقبل الأستروجين الطافر ألفا على طفرة واحدة أو أكثر تم اختيارها من المجموعة التي تتكون من D538G، Y537X 1، L536X 2، P535H، V534E، S463P، V392I، E380Q وتوليفات منها، حيث: X 1 هو S أو N أو C؛ وX 2 هو R أو Q. في بعض النماذج، يتم اختيار سرطان إيجابي ألفا لمستقبلات الاستروجين المقاوم للعقاقير من المجموعة التي تتكون من سرطان الثدي وسرطان الرحم وسرطان المبيض وسرطان الغدة النخامية.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862776338P | 2018-12-06 | 2018-12-06 | |
PCT/US2019/064980 WO2020118202A1 (en) | 2018-12-06 | 2019-12-06 | Methods for treating cancer in models harboring esr1 mutations |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210138A1 true JOP20210138A1 (ar) | 2023-01-30 |
Family
ID=69158304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0138A JOP20210138A1 (ar) | 2018-12-06 | 2019-12-06 | طرق علاج السرطان في نماذج تأوي طفرات esr1 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220016052A1 (ar) |
EP (1) | EP3890835A1 (ar) |
JP (2) | JP7497353B2 (ar) |
KR (1) | KR20210100135A (ar) |
AU (1) | AU2019392908A1 (ar) |
BR (1) | BR112021010141A2 (ar) |
CA (1) | CA3121918A1 (ar) |
EA (1) | EA202191256A1 (ar) |
IL (1) | IL283655A (ar) |
JO (1) | JOP20210138A1 (ar) |
MA (1) | MA54393A (ar) |
MX (1) | MX2021006412A (ar) |
SG (1) | SG11202105915UA (ar) |
WO (1) | WO2020118202A1 (ar) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL255148B2 (en) | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
-
2019
- 2019-12-06 WO PCT/US2019/064980 patent/WO2020118202A1/en active Application Filing
- 2019-12-06 JO JOP/2021/0138A patent/JOP20210138A1/ar unknown
- 2019-12-06 US US17/299,361 patent/US20220016052A1/en active Pending
- 2019-12-06 MX MX2021006412A patent/MX2021006412A/es unknown
- 2019-12-06 JP JP2021531817A patent/JP7497353B2/ja active Active
- 2019-12-06 EP EP19835569.5A patent/EP3890835A1/en active Pending
- 2019-12-06 BR BR112021010141-1A patent/BR112021010141A2/pt unknown
- 2019-12-06 MA MA054393A patent/MA54393A/fr unknown
- 2019-12-06 AU AU2019392908A patent/AU2019392908A1/en active Pending
- 2019-12-06 SG SG11202105915UA patent/SG11202105915UA/en unknown
- 2019-12-06 CA CA3121918A patent/CA3121918A1/en active Pending
- 2019-12-06 EA EA202191256A patent/EA202191256A1/ru unknown
- 2019-12-06 KR KR1020217020309A patent/KR20210100135A/ko active Search and Examination
-
2021
- 2021-06-02 IL IL283655A patent/IL283655A/en unknown
-
2024
- 2024-05-29 JP JP2024086821A patent/JP2024101017A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210100135A (ko) | 2021-08-13 |
JP2022511497A (ja) | 2022-01-31 |
SG11202105915UA (en) | 2021-07-29 |
CA3121918A1 (en) | 2020-06-11 |
JP2024101017A (ja) | 2024-07-26 |
JP7497353B2 (ja) | 2024-06-10 |
MX2021006412A (es) | 2021-07-21 |
WO2020118202A1 (en) | 2020-06-11 |
AU2019392908A1 (en) | 2021-06-10 |
US20220016052A1 (en) | 2022-01-20 |
EP3890835A1 (en) | 2021-10-13 |
IL283655A (en) | 2021-07-29 |
EA202191256A1 (ru) | 2021-10-06 |
BR112021010141A2 (pt) | 2021-08-24 |
MA54393A (fr) | 2021-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005561A (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco. | |
MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
JOP20210137A1 (ar) | طرق علاج سرطان مقاومة لمثبطات cdk4/6 | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
BR112016020953A2 (pt) | composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção | |
SA521421973B1 (ar) | عامل مضاد لمستقبل crf1، ومستحضرات صيدلانية وأشكال صلبة منها لعلاج فرط التنسج الكظري الخلقي | |
JOP20210005A1 (ar) | عوامل تحلل مستقبلات الإستروجين الانتقائية | |
PH12019500025A1 (en) | Cancer treatment combinations | |
UA124241U (uk) | Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози | |
EP4410291A3 (en) | Erbb receptor inhibitors | |
MX2019013071A (es) | Metodo de tratamiento inmunoterapeutico de un tumor. | |
JP2019520426A5 (ar) | ||
MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
MX2020013335A (es) | Metodos novedosos. | |
JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
MX2020011453A (es) | Combinaciones para tratar el cancer. | |
MX2017009047A (es) | Regimen de dosificacion para antagonistas de madcam. | |
PH12021550930A1 (en) | Drug Antibody Conjugates | |
SA520411635B1 (ar) | A2a مشتق حلقي مدمج كمثبط مستقبل | |
MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
JOP20210138A1 (ar) | طرق علاج السرطان في نماذج تأوي طفرات esr1 | |
CR20230018A (es) | Formas farmacéuticas de maleato de acalabrutinib | |
MX2021007687A (es) | Sales novedosas de degradadores selectivos de receptores de estrogeno. | |
ZA202200331B (en) | Naltrexone formulation |